Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 120
Filter
2.
Cutis ; 113(5): 224-225, 2024 May.
Article in English | MEDLINE | ID: mdl-39042133

ABSTRACT

Orodynia (OD) manifests as an unexplained burning sensation in the oral cavity, often persisting for years without clear clinical findings. Currently, there is no clear protocol for managing OD. We propose a systematic approach that aims to exclude common potential causes and attempt proactive treatments. Anecdotally, we have found that our structured approach improves clinical outcomes.


Subject(s)
Burning Mouth Syndrome , Humans , Burning Mouth Syndrome/therapy , Burning Mouth Syndrome/diagnosis
3.
Adv Exp Med Biol ; 1447: 83-90, 2024.
Article in English | MEDLINE | ID: mdl-38724786

ABSTRACT

As with other inflammatory skin disorders, atopic dermatitis has a tendency to cause stress and also be exacerbated by it. Patients with atopic dermatitis have several disease-associated stressors, some of which include physical discomfort due to itching and altered appearance due to flare-ups. These stressors have been shown to effect patients psychosocially by altering sleep patterns, decreasing self-esteem, and interfering with interpersonal relationships. In combination with its direct effect on patients, atopic dermatitis also causes stress for parents and caregivers. Studies suggest that atopic dermatitis is strongly correlated with co-sleeping habits, which can negatively impact the health and mood of parents or caregivers. It has also been reported to interfere with the formation of a strong mother-child relationship. In order to optimize treatment for patients with atopic dermatitis, it is important to note the impact that it has on quality of life. By implementing patient counseling, sleep-targeted therapies, and the use of quality of life (QoL) indices, atopic dermatitis patients and caregivers have the potential to experience greater satisfaction with treatment.


Subject(s)
Dermatitis, Atopic , Quality of Life , Stress, Psychological , Dermatitis, Atopic/psychology , Humans , Stress, Psychological/psychology , Stress, Psychological/complications , Caregivers/psychology , Sleep/physiology
9.
J Dermatolog Treat ; 34(1): 2251619, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37674258

ABSTRACT

AIM: Low-level light therapy (LLLT) may offer an adjunctive therapeutic tool for inflammatory skin conditions. This pilot study assessed the efficacy of a red/near-infrared (NIR)-emitting fabric for psoriasis, polymorphous light eruption (PMLE), and alopecia areata (AA). METHODS: Fourteen patients (five with psoriasis, five with PMLE, and four with AA) were instructed to wear a red/NIR-emitting (Lumiton®) garment during the 12-week study. Efficacy was assessed subjectively by patient-reported improvement and objectively by the redness, thickness, and scale of elbow psoriasis plaques, the frequency of PMLE flares, and the Severity of Alopecia Tool (SALT) score. RESULTS: Three patients with psoriasis completed the study while two self-discontinued. The three patients who completed the study noted improvement and two had improvements in lesion redness, thickness, or scale, while one was clinically stable. Three patients with PMLE completed the study, and none had a disease flare during the study period. Three patients with AA completed the study: two reported disease improvement and all three had an improved SALT score. CONCLUSION: Use of a wellness apparel that emits red and NIR light may be associated with improved disease severity in patients with mild elbow psoriasis, PMLE, and limited AA. Limitations of this study include continuation on topical, intralesional, or systemic medications and small sample size.


Subject(s)
Alopecia Areata , Dermatitis, Contact , Psoriasis , Humans , Alopecia Areata/radiotherapy , Pilot Projects , Psoriasis/radiotherapy , Erythema , Technology
12.
JAMA Dermatol ; 159(6): 669-671, 2023 06 01.
Article in English | MEDLINE | ID: mdl-37043228

ABSTRACT

This case report describes a woman in her 50s with a large, crusted, erythematous plaque on the right chest that was consistent with a Hailey-Hailey disease flare.


Subject(s)
Pemphigus, Benign Familial , Humans , Cinacalcet/therapeutic use , Pemphigus, Benign Familial/diagnosis , Pemphigus, Benign Familial/drug therapy , Ointments , Tacrolimus
15.
Dermatol Ther ; 35(11): e15849, 2022 11.
Article in English | MEDLINE | ID: mdl-36131640

ABSTRACT

Atopic dermatitis (AD) is a common relapsing inflammatory skin condition associated with a high economic burden due to its chronicity and multitude of direct and indirect treatment costs. AD disproportionately impacts children and minority populations, and treatment choices are cost-prohibitive for many patients. Our objective was to describe the treatment and management of AD from a cost-conscious perspective. A review of the literature was conducted with PubMed using the following keywords: AD, cost, medications, treatment, management, efficacy, adherence, education, and prophylactic. The use of moisturizers prophylactically in high-risk infants who have yet to develop AD may reduce incidence of disease and associated costs. Increasing patient medication adherence and moisturizing between flares also reduces costs in AD. The use of corticosteroids as the first-line treatment is efficacious and cost-effective for mild cases of AD, however, in severe cases of AD corticosteroids alone are not sufficient. Systemic biologics are necessary in some patients with severe cases of AD; however, they are associated with high costs. Phototherapy, through portable home units, tanning beds, and natural sunlight are cost-effective alternatives. Effective management of AD improves with education programs for both the patient and their family, reducing long-term costs in the management of this disease. Reducing AD treatment costs requires consideration of prophylactic therapies, patient education, and should differ based on the severity of disease. A multifaceted approach to AD treatment reduces costs and health-care barriers.


Subject(s)
Dermatitis, Atopic , Child , Infant , Humans , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/epidemiology , Health Care Costs , Cost-Benefit Analysis , Skin , Incidence
18.
Rev Paul Pediatr ; 40: e2021134, 2022.
Article in English, Portuguese | MEDLINE | ID: mdl-35703724

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate the coronavirus disease 2019 (COVID-19) cutaneous manifestations described in pediatric patients and discuss their relevance for early diagnosis. DATA SOURCE: The study consisted of a systematic review of original articles indexed in PubMed and Embase databases, as well as gray literature articles found through Google Scholar. A search strategy, based on PICO (Patient, Intervention, Comparison, Outcome) Tool, with the terms "child," "infant," "childhood," "adolescents," "teenagers," "COVID-19," "SARS-CoV-2," and "skin manifestations," was performed to optimize the findings. The study did not restrict any article regarding language. DATA SYNTHESIS: Out of the 310 articles that initially met the inclusion criteria, 35 were selected for review, totalizing 369 patients. The most common COVID-19 cutaneous manifestations in children and adolescents were Chilblain-like lesions, presented in 67.5% of the cases, followed by erythema multiforme-like (31.7%) and varicella-like lesions (0.8%). The Chilblain-like lesions appeared 7.6 days (95%CI 7.4-7.8) after the viral infection and lasted for 17.5 days (95%CI 16.5-18.5), erythema multiforme-like lesions appeared in 9.5 days (95%CI 9-10) and lasted for 10.3 days (95%CI 9.1-11.5), and varicella-like lesions appeared in 12.3 days (95%CI 4-20.6) and lasted for 7 days. CONCLUSIONS: Knowledge of the different skin manifestations in children and adolescents with COVID-19 is essential for an early diagnosis and, consequently, the possibility of promptly care adoption as well as to interrupt the new coronavirus transmission chains in the current pandemic context.


Subject(s)
COVID-19 , Chickenpox , Chilblains , Erythema Multiforme , Skin Diseases , Adolescent , Child , Humans , Infant , SARS-CoV-2 , Skin Diseases/etiology
SELECTION OF CITATIONS
SEARCH DETAIL